Table 1 Characteristics of study population and unique index infection visits over the three year study period
Overall Study Population (n = 170,247) | |
|---|---|
Median age (IQR) at beginning of OSA program | 74 (69, 80) |
Female (n,%) | 97,568 (57.3%) |
Death within 30 days post index visit for the overall population (n,%) | 1,270 (0.8%) |
Any antibiotic prescription within 30 days post index visit for the overall population (n,%) | 86,436 (50.8%) |
Unique Index Visits for Infections of Interest (n = 397,534) | |
AECB | 119,215 (30.0%) |
Proportion prescribed any antibiotic within 30 days 35% | |
URTI | 185,946 (46.8%) |
Proportion prescribed any antibiotic within 30 days 62% | |
Pneumonia | 37,869 (9.5%) |
Proportion prescribed any antibiotic within 30 days 48% | |
UTI | 54,504 (13.7%) |
Proportion prescribed any antibiotic within 30 days 71% | |
Patients with a Unique Index Visit 1 (n = 397,534) | |
Antibiotic Use Within 30 days Following Unique Index Visit 1 | |
No antibiotic use | 200,794 (50.5%) |
Antibiotics other than macrolides and quinolones | 77,586 (39.4%) |
Macrolides | 61,331 (31.2%) |
Quinolones | 57,823 (29.4%) |
Levofloxacin | 32,631 (56.4%) |
Ciprofloxacin | 22,411 (38.8%) |
Moxifloxacin 2 | 2,578 (4.5%) |
Gatifloxacin 2 | 151 (0.3%) |
Ofloxacin 2 | 52 (0.1%) |